Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID Cohort Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04393155
Recruitment Status : Terminated (Grant application to fund this work was not funded. We won't be posting data for this study.)
First Posted : May 19, 2020
Last Update Posted : February 12, 2021
Sponsor:
Information provided by (Responsible Party):
Renee Stapleton, University of Vermont

Brief Summary:
The novel SARS-CoV-2 virus has quickly spread worldwide, with substantial morbidity and mortality. There is very limited understanding of the short- and longer-term inflammatory/immunological and clinical course. However, the investigators expect survivors from severe COVID-19 to experience persistent functional impairments, as demonstrated in prior studies of patients with acute respiratory distress syndrome (ARDS) and other acute viral illnesses. Notably, however, few studies have ever investigated the biologic mechanisms underlying these functional impairments. Understanding these features of COVID-19 will improve the ability to design acute therapies and recovery-focused interventions. To address these knowledge gaps, the investigators propose a two-center, 225 patient longitudinal prospective cohort study of hospitalized COVID-19 patients with acute respiratory failure. Researchers will perform an in-depth evaluation of inflammatory/immunological biomarkers, and physical, pulmonary, and neuropsychological clinical outcomes during hospitalization, and over 3-, 6-, and 12-month follow-up.

Condition or disease Intervention/treatment
COVID-19 Acute Respiratory Failure Other: COVID-19+ observational

Detailed Description:

The novel coronavirus (SARS-CoV-2) and associated COVID-19 illness has quickly spread worldwide, with substantial morbidity and mortality. Early data suggest that most patients with severe COVID-19 (i.e., experiencing acute respiratory failure (ARF) in an intensive care unit) may have cytokine release syndrome and other major effects on the innate and adaptive immune systems. However, there is limited understanding of both the inflammatory/immunological and the clinical course of COVID-19, with no robust data published beyond hospital discharge. Based on prior literature from acute viral illnesses, such as Ebola and Severe Acute Respiratory Syndrome (SARS), persistent functional impairments in COVID-19 survivors is expected. Despite the importance of these issues, very few studies have ever investigated the biological mechanisms underlying persistent functional impairments after ARF. Hence, understanding the short- and longer-term biological and clinical outcomes of patients with COVID-19, and investigating associations between inflammation and clinical outcomes is important to design acute therapies and recovery-focused interventions.

To address critical gaps in knowledge, the investigators propose a 2-center longitudinal cohort study of hospitalized COVID-19 patients via an Administrative Supplement to our existing grant (R01HL132887, MPIs Stapleton and Needham). Investigators will study COVID-19 patients with ARF who have either severe disease (requiring mechanical ventilation, non-invasive ventilation, or high flow nasal cannula oxygen support) or non-severe disease (new or increased supplemental oxygen requirement, without meeting severe criteria). Researchers will perform an in-depth evaluation of inflammatory/immunological, physical, pulmonary, and neuropsychological status during hospitalization, and over 3, 6, and 12-month follow-up. Feasibility for accomplishing this prospective study is demonstrated by 1) a successful existing collaboration between the University of Vermont (UVM) and Johns Hopkins University (JHU), supported by multiple NIH grants, and 2) the current and projected COVID-19 census at both hospital systems. The investigators have the existing infrastructure, expertise, and personnel to enroll 225 patients with COVID-19, and longitudinally follow survivors for 12 months, to investigate short-term and longer-term inflammatory/immunologic and clinical outcomes during this pandemic.

Layout table for study information
Study Type : Observational
Actual Enrollment : 16 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Understanding Immunology and Patient Outcomes of COVID-19: A 1-Year Longitudinal Follow-up Study of Hospitalized Patients
Actual Study Start Date : April 16, 2020
Actual Primary Completion Date : January 20, 2021
Actual Study Completion Date : January 25, 2021

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
COVID-19+
Hospitalized patients with acute respiratory failure (new oxygen requirement) due to COVID-19
Other: COVID-19+ observational
This is observational -- there is no intervention




Primary Outcome Measures :
  1. Six minute walk distance (6MWD) [ Time Frame: 3 months after hospital admission ]
    Exercise capacity


Secondary Outcome Measures :
  1. Six minute walk distance (6MWD) [ Time Frame: 6 months, 12 months after hospital admission ]
    Exercise capacity

  2. Hospital Anxiety and Depression Scale (HADS) [ Time Frame: 3 months, 6 months, 12 months after hospital admission ]
    Symptoms of anxiety and depression. Both anxiety and depression subscales are scored from 0-21, with higher scores indicating more symptoms.

  3. EuroQol Group standardized measure of health status (EQ-5D-5L) [ Time Frame: 3 months, 6 months, 12 months after hospital admission ]
    Health-related quality of life. The EQ-5D-5L is scored from 0-100, with a higher score indicating better health status.

  4. MoCA-BLIND [ Time Frame: 3 months, 6 months, 12 months after hospital admission ]
    Mental and Cognitive Functioning. The MoCA-BLIND is scored from 1-22, with higher scores indicating better cognitive function.

  5. Health Care Utilization Survey (HUS) [ Time Frame: 3 months, 6 months, 12 months after hospital admission ]
    Health Care Utilization

  6. Death [ Time Frame: 3 months, 6 months, 12 months after hospital admission ]
    Mortality

  7. Forced vital capacity (FVC) [ Time Frame: 3 months, 6 months, 12 months after hospital admission ]
    The maximum volume of gas expired when the patient exhales as forcefully and rapidly as possible after a maximal inspiration. Obtained by spirometry.

  8. Forced expiratory volume in 1 second (FEV1) [ Time Frame: 3 months, 6 months, 12 months after hospital admission ]
    Measure of the volume expired over the first second of an FVC maneuver. Obtained by spirometry

  9. 4-meter timed walk [ Time Frame: 3 months, 6 months, 12 months after hospital admission ]
    Gait speed

  10. Peripheral blood mononuclear cell type: CD4+ T cells (#cells/ml) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Measured by cell staining and flow cytometry. PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.

  11. Peripheral blood mononuclear cell type: CD8+ T cells (#cells/ml) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Measured by cell staining and flow cytometry. PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.

  12. Peripheral blood mononuclear cell type: B cells (#cells/ml) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Measured by cell staining and flow cytometry. PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.

  13. Peripheral blood mononuclear cell type: NK cells (#cells/ml) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Measured by cell staining and flow cytometry. PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.

  14. Peripheral blood mononuclear cell type: monocytes (#cells/ml) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Measured by cell staining and flow cytometry. PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.

  15. Circulating markers of inflammation: C-Reactive Protein (CRP) (mg/l) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.

  16. Circulating markers of inflammation: Interleukin 6 (IL-6) (pg/ml) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.

  17. Circulating markers of inflammation: Interleukin 8 (IL-8) (pg/ml) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.

  18. Circulating markers of inflammation: Interferon gamma (IFNg) (pg/ml) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.

  19. Circulating markers of inflammation: Interferon alpha (IFNa) (pg/ml) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.

  20. Circulating markers of inflammation: Tumor necrosis factor alpha (TNFa) (pg/ml) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.

  21. Circulating markers of inflammation: Interleukin 1 beta (IL-1b) (pg/ml) [ Time Frame: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admission ]
    Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.


Biospecimen Retention:   Samples With DNA
Blood, nasal swabs


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study will enroll patients hospitalized at participating medical centers who have a positive test result for COVID-19. These patients are expected to have a greater acuity of illness and burden of disease based on the fact that they require inpatient care. Enrolling hospitalized patients ensures a greater opportunity to collect serial biological specimens over the course of the illness due to proximity of the patient to medical and research staff and UVM laboratories.
Criteria

Inclusion Criteria:

  1. Adult (≥18 years old) at the time of consent
  2. Positive COVID-19 test result or highly suspicious for COVID-19 infection and have a test pending
  3. Acute Respiratory Failure (new requirement for supplemental oxygen or acute increase in required supplemental oxygen)

Exclusion Criteria:

  1. Expected death or withdrawal of life-sustaining treatments within 3 days
  2. Unable to walk ≥150 feet prior to COVID-19 (due to 6-minute walk test being primary outcome for in-person testing)
  3. Hemoglobin ≤7.0 at the time of consent
  4. Pre-existing cognitive/language impairment prohibiting clinical outcomes assessment
  5. Prior lung resection (due to spirometry as part of in-person outcome assessment)
  6. Unable to provide consent and no legally authorized representative (LAR) identified or reached by phone
  7. Pregnant
  8. Incarcerated
  9. Homelessness
  10. Physician declines patient enrollment (attending physician or study physician)
  11. Patient or LAR do not consent to participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04393155


Locations
Layout table for location information
United States, Vermont
University of Vermont College of Medicine
Burlington, Vermont, United States, 05405
Sponsors and Collaborators
University of Vermont
Layout table for additonal information
Responsible Party: Renee Stapleton, Professor of Medicine, University of Vermont
ClinicalTrials.gov Identifier: NCT04393155    
Other Study ID Numbers: 16-540
First Posted: May 19, 2020    Key Record Dates
Last Update Posted: February 12, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Insufficiency
Respiration Disorders
Respiratory Tract Diseases